|
The Organization:
The Chinese Biopharmaceutical Association (CBA) is a non-profit organization made
up of professionals who have an interest in bio-pharmaceutical research and/or technology
development. CBA was established in 1995 and its headquarters are located in the
State of Maryland, which is adjacent to the U.S. capital city of Washington D.C.
The majority of CBA members are Chinese scientists, researchers, or professors.
They work in government agencies, universities, research institutes as well as in
the biotechnology and pharmaceutical industries. Some are conducting pioneering
research with the National Institutes of Health (NIH), whereas others are directly
involved in the government regulatory process as officers of the Food and Drug Administration
(FDA) or in the field of intellectual property as patent attorneys or as patent
examiners with the Patent and Trademark Office (PTO). CBA's Executive Committee
consists of research, regulatory and management professionals who, in aggregate,
represent all sectors of the bio-pharmaceutical research and development communities
and the industry’s regulatory agencies.
The Mission:
CBA is committed to promoting science, technology, and business development in the
bio-pharmaceutical fields through information exchange and by fostering research
and business collaborations. It brings scientists and business practitioners together
and aims to establish links between basic and applied research, between academia
and industry, and between researchers and entrepreneurs. CBA is also committed to
facilitating all types of biopharmaceutical-focused collaborations between the United
States and China.
CBA's Approach:
CBA intends to accomplish its mission by serving as a liaison between individual
members for a myriad of scientific/technological and business needs. The goal is
to help to match up expert individual CBA members with appropriate local institutes
and companies that may be able to provide needed technical and manufacturing needs.
CBA also hopes to provide a productive link between entrepreneurs and investors.
By serving as a conduit between the bio-pharmaceutical industries in the United
States and China CBA seeks to encourage the adoption of advanced scientific knowledge
and new innovative technologies to China while also promoting business opportunities
in both countries. CBA members have expertise in all aspects of bio-pharmaceutical
fields ranging from expertise regarding recombinant DNA technology, large scale
protein production to gene therapy. Many of our members thoroughly understand the
FDA regulatory process and have hands-on experience with implementation of GMP and
GLP manufacturing processes, various legal and legislative issues related to the
commercial development of diagnostic tests, medical devices and therapeutic drugs
as well as a range of business investment, financing, marketing and management know-how.
CBA members’ combined knowledge, skills and experience constitutes a rich resource
for the bio-pharmaceutical industry sectors in both the U.S. and China.
|